immunotherapy
Rectal cancer disappeared in all patients involved in a small clinical trial of a new immunotherapy treatment, according to updated results released this month. The study was a collaboration between the US-based Memorial Sloan Kettering Cancer Center (MSK) and the pharmaceutical company GSK. It looked at a new drug called dostarlimab-gxly to treat patients with a specific type of rectal cancer caused by a genetic mutation. “As a clinician, I’ve seen firsthand the debilitating impact of standard treatment of dMMR rectal cancer and am thrilled about the potential of dostarlimab-gxly in these pat...
Euronews (English)
A promising human clinical trial on four patients may pave the way for a new treatment of glioblastoma, an aggressive form of brain cancer. Researchers from the University of Florida in the US developed an mRNA cancer vaccine which triggers the immune system to target the tumour. Approximately 19,000 individuals in the EU are believed to be affected by this condition annually. The approach to treating glioblastoma has seen little evolution since the early 2000s, primarily relying on chemotherapy, radiotherapy, and surgical interventions. The average survival duration for patients diagnosed wit...
Euronews (English)
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら